Comparing SQZ Biotechnologies (NYSE:SQZ) and PharmaCyte Biotech (OTCMKTS:PMCBD)

Insider & Institutional Ownership

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares SQZ Biotechnologies and PharmaCyte Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16 million	0.05	-$79.46 million	($2.61)	-0.01
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

PharmaCyte Biotech has lower revenue, but higher earnings than SQZ Biotechnologies.

Profitability

This table compares SQZ Biotechnologies and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Volatility & Risk

SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.